DelMar Pharmaceuticals (DMPI) Stock Price Up 15.2%

Shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) rose 15.2% on Monday . The stock traded as high as $1.75 and last traded at $1.67. Approximately 2,860,300 shares traded hands during trading, an increase of 11% from the average daily volume of 2,577,425 shares. The stock had previously closed at $1.45.

Separately, HC Wainwright set a $12.00 price objective on shares of DelMar Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, January 4th.

The firm has a market cap of $34.13, a PE ratio of -2.32 and a beta of 1,227.20.

DelMar Pharmaceuticals (NASDAQ:DMPI) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). sell-side analysts expect that DelMar Pharmaceuticals Inc will post -0.54 EPS for the current year.

In other DelMar Pharmaceuticals news, CEO Saiid Zarrabian purchased 60,900 shares of DelMar Pharmaceuticals stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average price of $0.82 per share, for a total transaction of $49,938.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

A number of hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP purchased a new stake in DelMar Pharmaceuticals in the 3rd quarter valued at $306,000. Sabby Management LLC purchased a new stake in DelMar Pharmaceuticals in the 2nd quarter valued at $1,484,000. Finally, Franklin Resources Inc. purchased a new stake in DelMar Pharmaceuticals in the 2nd quarter valued at $2,477,000. Hedge funds and other institutional investors own 16.91% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit